Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

Blood. 2020 Mar 12;135(11):862-865. doi: 10.1182/blood.2019002920.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, CD19 / immunology*
  • Antigens, CD19 / metabolism
  • Antigens, Neoplasm / immunology*
  • Humans
  • Immunotherapy, Adoptive*
  • Lymphoma, B-Cell / immunology*
  • Lymphoma, B-Cell / therapy*
  • Male
  • Middle Aged
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Chimeric Antigen / genetics
  • Receptors, Chimeric Antigen / metabolism
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / metabolism*
  • Treatment Outcome

Substances

  • Antigens, CD19
  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen